Skip to content Skip to footer
Subscribe Now

NEWS

TelaBio
TELA Bio Launches OviTex Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair in the EU
Shots: TELA Bio has launched OviTex Inguinal in the EU for laparoscopic & robotic-assisted inguinal hernia repair; OviTex Inguinal to be showcased at EHS 2025 OviTex Inguinal is available in 2 trocar-compatible configurations, consisting of 3 or 4 layer anatomically shaped devices that provide surgeons with flexible options designed to meet pts, technique, or procedure-specific needs…
June 4, 2025
Zoetis
Zoetis Launches AI Masses to Detect Skin and Lymph Lesions
Shots: Zoetis has launched AI Masses for its Vetscan Imagyst analyzer to detect neoplastic cells in animals; AI Masses is available in North America starting Jun 2, 2025 AI Masses uses advanced deep learning algorithms to identify & classify common skin/subcutaneous masses & lymph node lesions in real time, improving point-of-care access & client satisfaction,…
June 4, 2025
Takeda
Takeda’s Adcetris Regimen Receives the EC’s Approval to Treat Newly Diagnosed Hodgkin Lymphoma
Shots: The EC has approved Adcetris (brentuximab vedotin) + ECADD (etoposide, cyclophosphamide, doxorubicin, dacarbazine & dexamethasone) to treat adults with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma following CHMP’s positive opinion in Apr 2025 Approval was based on P-III (HD21) trial assessing Adcetris + ECADD vs escalated doses of BEACOPP in above pts,…
June 4, 2025
Regeneron Enters a ~$2B In-Licensing Deal with Hansoh Pharma for HS-20094, Expanding its Obesity Portfolio
Shots: Regeneron has entered into an in-licensing agreement with Hansoh for exclusive global clinical development & commercialization rights of HS-20094, excl. Mainland China, Hong Kong & Macau As per the deal, Hansoh will receive $80M upfront & ~$1.93B in development, regulatory & sales milestones, with low double digits royalties on sales in Regeneron-licensed areas HS-20094…
June 3, 2025
Load more